Docetaxel, doxorubicin and cyclophosphamide (the TAC regimen): an effective adjuvant treatment for operable breast cancer

Author： Martin Miguel  

Publisher： Future Medicine

ISSN： 1745-5057

Source： Women's Health, Vol.2, Iss.4, 2006-07, pp. : 527-537

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Outcomes and Cost‐effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer

By  

THE BREAST JOURNAL, Vol. 21, Iss. 6, 2015-11 ,pp. : 658-664

John Wiley & Sons Inc

Access to resources Recommend Favorite

Doxorubicin-Docetaxel Sequential Schedule: Results of Front-Line Treatment in Advanced Breast Cancer

By  

Oncology, Vol. 63, Iss. 3, 2002-10 ,pp. : 205-212

Karger

Access to resources Recommend Favorite

Utility of neoadjuvant chemotherapy in the treatment of operable breast cancer

By  

ANZ JOURNAL OF SURGERY, Vol. 85, Iss. 5, 2015-05 ,pp. : 315-320

John Wiley & Sons Inc

Access to resources Recommend Favorite

Verbal memory in breast cancer patients treated with chemotherapy with doxorubicin and cyclophosphamide

By  

EUROPEAN JOURNAL OF CANCER CARE (ELECTRONIC), Vol. 27, Iss. 1, 2018-01 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel plus Doxorubicin (D4) for First-Line Treatment of Metastatic Breast Cancer

By  

Oncology, Vol. 79, Iss. 3-4, 2011-03 ,pp. : 204-210

Karger

Access to resources Recommend Favorite